Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1997
Business Overview: Neurocrine is engaged in the discovery and development of pharmaceutical products for central nervous and immune system disorders. The company has not generated product sales revenue and relies on strategic alliances, sponsored research, and milestone payments for income. As of September 30, 1997, the company had a cumulative deficit of approximately $5.0 million.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1997 |
Nine Months Ended Sep 30, 1997 |
Nine Months Ended Sep 30, 1996 |
|---|---|---|---|
| Total Revenues | $6,240,779 | $19,895,863 | $9,858,359 |
| Net Income (Loss) | $812,511 | $5,057,307 | $1,377,075 |
| EPS (Diluted) | $0.04 | $0.28 | $0.09 |
| Operating Expenses | $6,564,414 | $18,082,191 | $10,352,069 |
| Cash & Equivalents | $15,094,554 (as of Sep 30, 1997) | ||
| Short-term Investments | |||
| Total Liquidity | $68,926,906 (Cash + Investments) | ||
| Current Liabilities | $5,271,682 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues for the nine months ended September 30, 1997, increased to $19.9 million from $9.9 million in the prior year period. This 102% increase was driven by higher sponsored research fees and milestone payments from corporate collaborations.
- Expense Increases: Research and development (R&D) expenses rose to $14.0 million (from $8.3 million) and General and Administrative (G&A) expenses rose to $4.1 million (from $2.0 million). Increases were attributed to expanded scientific/clinical personnel, business development activities, and patent prosecution costs.
- Profitability: The company reported net income of $5.1 million for the nine-month period, compared to $1.4 million in the prior year. This improvement was primarily due to the surge in collaboration revenues outpacing the increase in operating expenses.
- Cash Flow: Net cash provided by operating activities turned positive at $1.5 million for the nine months ended September 30, 1997, compared to a net use of $3.3 million in the prior year period.
Outlook, Risks, and Management Commentary
- Future Profitability: Management does not anticipate continuing to generate net income. Operating expenses are expected to rise significantly as products advance through clinical development stages, likely resulting in future operating losses.
- Liquidity Position: As of September 30, 1997, the company held $68.9 million in cash, cash equivalents, and short-term investments. Management believes these resources, combined with interest income and future collaboration payments, will satisfy funding requirements through at least the year 2000.
- Capital Expenditures: In May 1997, the company purchased land for $5.0 million. In July 1997, it sold a parcel to a related entity (Science Park Center LLC) and entered a 15-year lease to construct a new facility, with an option to purchase the facility later.
- Risks: Key risks include the uncertainty of clinical trial results, regulatory approval processes, patent enforcement, and the potential inability to secure additional funding if current resources are depleted. The company may need to curtail programs or relinquish technology rights if funding is unavailable.
Investor Verification Checklist
- Revenue Sustainability: Verify the terms and duration of the strategic alliances driving the current revenue spike, as product sales are not expected in the foreseeable future.
- Burn Rate vs. Runway: Confirm the projected increase in R&D and G&A expenses against the $68.9 million liquidity position to validate the "through 2000" funding claim.
- Related Party Transactions: Review the details of the land sale and lease agreement with Science Park Center LLC to ensure fair market value and terms.
- Clinical Milestones: Assess the status of clinical trials for product candidates, as future milestone payments depend on successful progression.
- EPS Methodology: Note that the company is required to adopt FASB Statement No. 128 by December 31, 1997, which will change the calculation of basic and diluted earnings per share.